Jeffrey Clarke
0000-0001-5647-0245
Publication & Citation Trends
Publications
192 total
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Cited by 0
Semantic Scholar
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis OA
Cited by 4
Semantic Scholar
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC‒A Brief Report.
Cited by 7
Semantic Scholar
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer
Cited by 2
Semantic Scholar
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity
Cited by 3
Semantic Scholar
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer OA
Cited by 0
Semantic Scholar
Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial.
Cited by 11
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(73)
CAR-T cell therapy research
(54)
Lung Cancer Treatments and Mutations
(51)
Lung Cancer Research Studies
(23)
Gastrointestinal Tumor Research and Treatment
(22)
Affiliations
Ontario Institute for Cancer Research
University of North Texas
University of British Columbia Hospital
Guangxi Medical University
Duke University